These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12709295)

  • 21. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
    Doherty GA; Miksad RA; Cheifetz AS; Moss AC
    Inflamm Bowel Dis; 2012 Sep; 18(9):1608-16. PubMed ID: 21905173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
    Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
    Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
    Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
    Punekar YS; Sunderland T; Hawkins N; Lindsay J
    Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on infliximab in Crohn disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    BioDrugs; 2006; 20(1):67-70. PubMed ID: 16573354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.
    Kaplan GG; Hur C; Korzenik J; Sands BE
    Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1509-20. PubMed ID: 17931345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint.
    Hilsden R
    Can J Gastroenterol; 2002 Dec; 16(12):865-8. PubMed ID: 12522477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
    Kay M; Wyllie R
    Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
    [No Abstract]   [Full Text] [Related]  

  • 32. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 33. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Ruffolo C; Scarpa M; Bassi N
    N Engl J Med; 2010 Sep; 363(11):1086-7; author reply 1087-8. PubMed ID: 20848681
    [No Abstract]   [Full Text] [Related]  

  • 34. Management for severe Crohn's disease: a lifetime cost-utility analysis.
    Jaisson-Hot I; Flourié B; Descos L; Colin C
    Int J Technol Assess Health Care; 2004; 20(3):274-9. PubMed ID: 15446756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials.
    Kobelt G; Sobocki P; Sieper J; Braun J
    Int J Technol Assess Health Care; 2007; 23(3):368-75. PubMed ID: 17579941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
    Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
    Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
    Kobelt G; Eberhardt K; Geborek P
    Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
    Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.